Stack · Synergy

KLOW Stack Dosage Guide

GHK-Cu + KPV + BPC-157 + TB-500

The KLOW stack is a four-peptide healing blend sold as a single pre-mixed 80 mg vial — GHK-Cu 50 mg + KPV 10 mg + BPC-157 10 mg + TB-500 10 mg. It is the anti-inflammatory extension of the popular "Glow" blend (GHK-Cu + BPC-157 + TB-500): adding

Last updated · 2026-07-22

Healing & Recovery Skin & Hair Gut Health aka GHK-Cu + KPV + BPC-157 + TB-500 aka KLOW blend aka KLOW 80mg blend aka KLOW peptide stack aka Clow stack

📋 Full KLOW Stack dosage chart — reconstitution, tiered protocols & unit math →

Buy this stack

Single Vendor

All components from Particle Peptides

$211.96 total

Component breakdown (4 items)

GHK-Cu 50 mg $67.99
KPV 5 mg $31.99
BPC-157 5 mg $31.99
TB-500 10 mg $79.99

Cheapest Split $112.64 across 2 vendors Save $99.32

Compound	Vendor	Size	Price
GHK-Cu	Swiss Chems	mg	$24.70
KPV	Particle Peptides	5 mg	$31.99
BPC-157	Particle Peptides	5 mg	$31.99
TB-500	Swiss Chems	mg	$23.96

Components

GHK-Cu

Copper-binding tripeptide that activates tissue remodeling, collagen/elastin synthesis, anti-inflammatory gene expression, DNA repair, and stem cell recruitment. Resets expression of 4,000+ genes toward a younger profile.

Half-life: ~1 hour (injectable); variable topical absorption

KPV

C-terminal tripeptide of alpha-MSH — potent anti-inflammatory via NF-kB pathway inhibition; enters nucleus to directly suppress inflammatory transcription; melanocortin receptor-independent action

Half-life: ~15-30 minutes (estimated)

BPC-157

Upregulates growth hormone receptors, modulates nitric oxide system (NO/NOS), promotes angiogenesis, activates FAK-paxillin pathway, modulates dopaminergic and serotonergic systems

Half-life: ~4 hours (stable in gastric juice — unique among peptides)

TB-500

Upregulates actin, promotes cell migration via Akt/mTOR pathway, reduces inflammation, stimulates angiogenesis, modulates NF-κB

Half-life: ~14 days

Overview

The KLOW stack is a four-peptide healing blend sold as a single pre-mixed 80 mg vial — GHK-Cu 50 mg + KPV 10 mg + BPC-157 10 mg + TB-500 10 mg. It is the anti-inflammatory extension of the popular “Glow” blend (GHK-Cu + BPC-157 + TB-500): adding KPV layers a dedicated anti-inflammatory tripeptide on top of Glow’s collagen-and-repair base, which is why the same formula also circulates under the name “Clow.”

The appeal is convenience plus breadth. One injection covers four complementary mechanisms — copper-peptide skin and matrix remodeling, systemic tissue repair, local growth-factor drive, and inflammation control — making KLOW a favorite for skin regeneration, post-injury and post-surgical recovery, and gut/inflammatory-skin concerns in a single protocol.

Mechanism Synergy

Each component covers a different lane of the repair-and-renewal process:

GHK-Cu (Copper-Peptide Remodeler)

Delivers copper to skin, hair, and wound tissue; drives collagen and elastin synthesis
Broadly resets gene expression toward a younger, regenerative profile (Pickart & Margolina reviews)
Antioxidant and tissue-remodeling effects; supports gut tight-junction integrity
The bulk of the blend by mass (50 of 80 mg) — the “renewal” backbone

KPV (Anti-Inflammatory Tripeptide)

The C-terminal Lys-Pro-Val fragment of α-MSH
Downregulates NF-κB and pro-inflammatory cytokine signaling
Studied for inflammatory bowel conditions and inflammatory skin (Dalmasso et al. and related work)
The component that separates KLOW/Clow from plain Glow — best for inflammatory or gut-driven presentations

BPC-157 (Local Repair Driver)

Upregulates VEGF and EGF; activates nitric-oxide signaling for blood flow to injured tissue
Stimulates fibroblast proliferation and collagen synthesis
Gastroprotective — heals gut lining and protects against NSAID damage (Sikiric et al., 1993–2024)

TB-500 (Systemic Repair Orchestrator)

Sequesters G-actin, driving cell migration of endothelial cells, keratinocytes, and stem cells toward injury
Suppresses excessive inflammation; upregulates laminin and fibronectin for matrix remodeling
Long half-life (~14 days) — works systemically regardless of injection site (Sosne et al., thymosin β4 wound-healing work)

Combined effect: GHK-Cu and BPC-157 build the regenerative environment (matrix, blood flow, growth factors), TB-500 recruits the cellular workforce to populate it, and KPV keeps the inflammatory tone in check so repair proceeds cleanly. It hits skin, connective tissue, and gut from four angles at once.

Protocol

KLOW is dosed as a fixed-ratio blend — you titrate the vial, not the individual peptides.

Reconstitution

Reconstitute the 80 mg vial with 2 mL bacteriostatic water. That yields:

Component	Concentration	Per 10 units (0.1 mL)	Per 20 units (0.2 mL)
GHK-Cu	25 mg/mL	2.5 mg	5 mg
KPV	5 mg/mL	0.5 mg	1 mg
BPC-157	5 mg/mL	0.5 mg	1 mg
TB-500	5 mg/mL	0.5 mg	1 mg

(Units are on a U-100 insulin syringe; 10 units = 0.1 mL.)

Dosing

Start conservative: 10 units (0.1 mL) subcutaneously daily for 3–5 days to assess tolerance.
Standard: 10–20 units (0.1–0.2 mL) subcutaneously daily.
Inject into subcutaneous fat (abdomen or flank). Rotate sites.
One 2-mL-reconstituted vial lasts ~10–20 days at 10–20 units/day.

Timing & cycling

The blend is timing-flexible; most users dose once daily.
TB-500 caveat: because TB-500 has a ~14-day half-life, daily blend dosing delivers more TB-500 than a typical standalone 2–5 mg/week schedule and it accumulates. Many users dose the blend every other day or 4–5 days/week to moderate cumulative TB-500 while keeping the shorter-half-life components (GHK-Cu, KPV, BPC-157) effective.
Run 4–6 weeks, then reassess; align with a 4–8 week GHK-Cu cycle and take a washout before repeating.
Store reconstituted blend at 2–8 °C and use within 28 days.

When to dose components separately instead

Because the ratio is fixed, you cannot independently tune each peptide. If you want compound-level control — for example, higher weekly TB-500 for a specific tendon injury, or BPC-157 only for gut work — dose the components individually (see the Wolverine and Glow protocols) rather than the blend.

Evidence

Preclinical: Each of the four components has its own body of animal and in-vitro data — GHK-Cu on collagen/gene expression and wound healing (Pickart), KPV on NF-κB/anti-inflammatory signaling (Dalmasso et al. and related gut/skin work), BPC-157 on tendon/ligament/gut repair (Sikiric et al.), and TB-500/thymosin β4 on corneal, cardiac, and dermal healing (Sosne et al.).

Combination: There are no published human studies on the KLOW blend itself — its rationale is mechanistic complementarity plus community use. The most-cited real-world account is dermatologist-adjacent educator David DeMesquita’s Glow/Clow case reports (notable skin-tightening results), which are anecdotal, not controlled data.

Regulatory: None of the four peptides is FDA-approved for these uses; all are research-use-only in the US. BPC-157 was placed on the FDA’s Category 2 list in 2024 and removed from it in April 2026 — removal is not authorization; it is now in no interim category and not on the 503A bulks list. Treat community dosing guides as starting points, not medical guidance.

Considerations

Contraindications:

Active cancer or significant cancer risk — GHK-Cu and BPC-157 are pro-angiogenic and could theoretically support tumor vascularization. Avoid.
Pregnancy / breastfeeding — insufficient safety data.
Anticoagulant use — monitor, given BPC-157’s nitric-oxide modulation.

Side effects (generally mild): injection-site redness or swelling, transient nausea or headache, and lethargy during early TB-500 loading. A copper taste or mild flushing can accompany the GHK-Cu fraction.

Regulatory status: research-use-only in the US. BPC-157, TB-500 and KPV are not on the 503A bulks list and are in no FDA interim category — no lawful compounding route. Non-injectable GHK-Cu is on the Category 1 “Under Evaluation” list (enforcement discretion, not approval); injectable GHK-Cu is not. All four are prohibited in competitive sport (WADA/USADA).

Sourcing: KLOW is available as a pre-mixed 80 mg blend from several vendors, or you can source each component individually and combine them yourself. Live per-component pricing and vendor options are below.

Frequently Asked Questions

What is the KLOW stack?

KLOW is an 80 mg pre-mixed peptide blend — GHK-Cu 50 mg, KPV 10 mg, BPC-157 10 mg, and TB-500 10 mg — used for skin regeneration, tissue and injury repair, and gut or inflammatory support. It is the anti-inflammatory, KPV-added extension of the Glow blend.

What is the difference between KLOW and Glow?

Glow is GHK-Cu + BPC-157 + TB-500 for skin, hair, and healing. KLOW adds KPV, a dedicated anti-inflammatory tripeptide, making it better for inflammatory skin, gut issues, or autoimmune-adjacent concerns. The same KLOW formula is also sold as Clow.

How do you dose the KLOW blend?

Reconstitute the 80 mg vial with about 2 mL bacteriostatic water and inject subcutaneously once daily, starting around 10 units (0.1 mL) to assess tolerance and working up to 10–20 units. Because TB-500 has a roughly 14-day half-life, some people dose every other day to avoid over-accumulating it. Store reconstituted blend at 2–8 °C and use within 28 days.

Is KLOW FDA-approved?

No. All four peptides are research-use-only in the US. None of BPC-157, TB-500 or KPV is on the 503A bulks list or in any of FDA's interim Category 1, 2 or 3 lists, so there is no lawful compounding route for them; GHK-Cu is on the Category 1 "Under Evaluation" list for non-injectable routes only, which is enforcement discretion rather than approval. An FDA advisory committee recommended BPC-157, TB-500 and KPV for the 503A bulks list on July 23, 2026, but the vote is advisory, FDA has not adopted it, and compounding them is not permitted. Community dosing guides are a starting point, not medical advice. Avoid with active cancer or during pregnancy.